We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

DiaMedica Therapeutics Inc (DMAC) NPV

Sell:$1.77 Buy:$2.47 Change: $0.20 (8.00%)
Market closed |  Prices as at close on 18 May 2022 | Switch to live prices |
Change: $0.20 (8.00%)
Market closed |  Prices as at close on 18 May 2022 | Switch to live prices |
Change: $0.20 (8.00%)
Market closed |  Prices as at close on 18 May 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for neurological and kidney diseases, such as acute ischemic stroke (AIS) and chronic kidney disease (CKD). The Company's lead product DM199 mimics the behavior of naturally occurring human kallikrein-1 (KLK1) proteins to preserve and restore circulation to stroke-damaged tissue and improve overall kidney function. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. DM199 therapy has the potential to improve circulation and overall function of critical systems, as well as reduce inflammation and oxidative stress. The Company also has other product pipelines for IgA Nephropathy and African Americans with CKD.

Contact details

Two Carlson Parkway, Suite 260
United States
+1 (763) 4965454

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$63.20 million
Shares in issue:
26.44 million
US dollar

Key personnel

  • Rick Pauls
    President, Chief Executive Officer, Director
  • Scott Kellen
    Chief Financial Officer, Corporate Secretary
  • Sydney Gilman
    Vice President - Regulatory Affairs
  • Timothy Mccarthy
    Managing Director, Relationship Manager
  • Harry Alcorn
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.